TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05977699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol aqueous solution
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol pressurized metered dose inhaler
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
Study: NCT04276142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ceprica (additional to treatment as usual)
Description: ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: active control intervention (additional to treatment as usual)
Description: the active control intervention contains psychoeducational content regarding migraine
Study: NCT06565416

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Strategies
Description: Culturally centering screening and brief intervention for chronic pain and opioid misuse/opioid use disorder among American Indian/Alaska Native clients
Study: NCT05620082

Intervention type: DIETARY_SUPPLEMENT
Intervention: Standard liquid-based oral nutritional supplement
Description: An anonymous ready-made drink supplement: 125g, 306kcal, 18.3g protein.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortified porridge
Description: Vital Daily High Protein Oats (Adams Vital Nutrition Ltd.): 157g, 230kcal, 15g protein.
Study: NCT06121271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177 DOTATATE (Lutathera®)
Description: Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177 DOTATATE (Lutathera®)
Description: Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
Study: NCT04347304

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate (20 grams) per day providing 508 mg of polyphenols
Description: subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
Study: NCT05408156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insoles
Description: semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Insoles
Description: semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
Study: NCT04347304

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: white chocolate (20 grams) with no polyphenols
Description: subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
Study: NCT06382233

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of Diagnostic Biomarkers
Description: Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of Diagnostic Biomarkers
Description: Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.
Study: NCT06527118

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVITIES TO LEARN SELF CARE SKILLS
Description: This activity program, which was prepared to develop self-care skills, aims to teach self-care skills of children with intellectual disabilities by having fun. The program was prepared by the educator and finalized after the approval of expert opinions.
Study: NCT05712720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Group 1
Description: RZ402 50 mg oral tablet, once daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Group 2
Description: RZ402 200mg oral tablet, once daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Group 3
Description: RZ402 400mg oral tablet, once daily for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Group 4
Description: Placebo, once daily for 3 months
Study: NCT05455528

Intervention type: DIAGNOSTIC_TEST
Intervention: estimated GFR calculation
Description: The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
Study: NCT06374693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: * Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart.
Study: NCT05047991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
Study: NCT06325150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting glasses
Description: Assess the capacity of 20 min use of AYO light emitting glasses on different outcomes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light emitting glasses
Description: Assess the capacity of 20 min use of AYO light emitting glasses on different outcomes
Study: NCT06374693

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Vagus Nerve Stimulation
Description: The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
Study: NCT06713954

Intervention type: BEHAVIORAL
Intervention: Dietary assessment
Description: Dietary intake data will be collected using the Snap-N-Send method, a tool with enhanced validity for assessing athlete total energy intake, where participants will take photographs of their meals and share them via WhatsApp directly with the researcher. Before the study commences, participants will receive standardised instructions on photographing food and adding details in the message such as title, portion sizes and ingredients alongside each photo to enhance data precision. The principal investigator will input these photographs with the added information into Nutritics dietary analysis software, where food weights, portion sizes, and nutritional content will be estimated and calculated. Nutritics will then calculate dependent variables and convert it into a food diary report, aggregating the three days of food diary into average intake.
Study: NCT06722131

Intervention type: OTHER
Intervention: Sampling
Description: Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up~* The considered samples are as follows :~  * Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)~ * Infection site sample if applicable :~* Urine (10 mL)~* Stool (1 mL)~* CSF (1 mL)~* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)~* Nasopharyngeal swab (one swab)~* Genital swab (one swab)~* Skin swab (one swab)~* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)
Study: NCT04714710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Potassium Canrenoate
Description: Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Sodium Chloride 0.9 %
Description: Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room.
Study: NCT05933057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
Study: NCT04856488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine-Potassium Iodide 5%-10% Oral and Topical Solution
Description: Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
Study: NCT04732884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartsens, Gelenic AG; with biofeedback
Description: The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartsens, Gelenic AG; without biofeedback
Description: Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
Study: NCT06533410

Intervention type: DIAGNOSTIC_TEST
Intervention: The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
Description: The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
Study: NCT06509802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE)
Description: This study will be a two-arm randomised controlled trial to examine the efficacy of the We-SMILE for pre-practicum social work and/or counselling students by comparing to the We-SMILE intervention group and the no-intervention training-as-usual group.
Study: NCT06512753

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: HCQ (15) is administered orally at a dosage of 400 mg daily.

Intervention type: DRUG
Intervention: Methotrexate
Description: MTX (16) is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
Study: NCT05241340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy + pelvic lymph node dissection + urinary diversion
Description: This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted.~Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis.
Study: NCT04748640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Knife VIM thalamotomy
Description: Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
Study: NCT04648267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast and bolster placement duration
Description: The intervention is increasing the duration of cast and bolster placement on split thickness skin graft sites.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: This will be standard of care - the patient will have his cast and bolster on for 5-7 days
Study: NCT05196113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sipIT
Description: Participants receive education and digital tools to monitor their fluid intake and just-in-time text messages to remind them when they have lapsed in regular fluid intake.
Study: NCT05489302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary skeletal expander with protraction face mask with Alt-RAMEC protocol.
Description: The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by Alt-RAMEC protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary skeletal expander with protraction face mask with conventional protocol
Description: The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by conventional protocol
Study: NCT06415032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy with Quilting sutures without drain placement
Description: The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy with Conventional sutures with drain placement
Description: The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
Study: NCT05629741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT06507709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low volume CBCT
Description: 3-D imaging used during dental practice
Study: NCT06487390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Pro training intervention
Description: Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
Study: NCT05662319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotting factor concentrates (CFC) or bypassing agents (BPA)
Description: * Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin concentrate (ATIIIC)
Description: Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
Study: NCT06133465

Intervention type: PROCEDURE
Intervention: Surgical wide local excision
Description: Surgical excision of breast carcinoma

Intervention type: PROCEDURE
Intervention: Surgical wide local excision
Description: Surgical excision of breast carcinoma

Intervention type: PROCEDURE
Intervention: Cavity shaving
Description: Cavity shaving of resection margins to guarantee oncological safety

Intervention type: PROCEDURE
Intervention: Cavity shaving
Description: Cavity shaving of resection margins to guarantee oncological safety

Intervention type: PROCEDURE
Intervention: Excision margin surgical clearance
Description: Surgical clearance of involved and/or closed excision margins

Intervention type: PROCEDURE
Intervention: Excision margin surgical clearance
Description: Surgical clearance of involved and/or closed excision margins

Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: Adjuvant radiotherapy

Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: Adjuvant radiotherapy

Intervention type: BIOLOGICAL
Intervention: Adjuvant Hormone Therapy
Description: Adjuvant hormone therapy

Intervention type: BIOLOGICAL
Intervention: Adjuvant Hormone Therapy
Description: Adjuvant hormone therapy